SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants
Rhea-AI Summary
SINTX Technologies (NASDAQ:SINT) signed a supply agreement with Evonik on Dec 1, 2025 to manufacture its patented silicon nitride–PEEK (SiN/PEEK) compound for AI‑assisted, 3D‑printed patient‑specific implants. Evonik will produce SiN/PEEK to SINTX specifications at commercial scale, enabling immediate manufacture at SINTX’s U.S. facility.
The compound targets antipathogenic surface behavior, osteogenic support, improved imaging vs standard PEEK, and scalable filament supply for humanitarian vertebral body replacement and future regulatory pathways.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SINT declined 21.20%, reflecting a significant negative market reaction. Argus tracked a peak move of +2.2% during that session. Argus tracked a trough of -23.5% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $16M at that time. Trading volume was very high at 3.8x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, SINT fell 5.16% while close peers showed mixed, smaller moves (e.g., INBS up 0.64%, TNON up 0.88%, XAIR down 0.9%, CODX down 0.46%), pointing to a stock-specific move rather than a broad medical devices trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Investor conference | Neutral | +4.5% | Participation in Sidoti virtual investor conference with webcast and 1x1 meetings. |
| Dec 01 | AI supply agreement | Positive | -21.2% | Signed EVONIK supply deal for SiN/PEEK AI-assisted 3D-printed implants. |
| Nov 13 | Q3 update & FDA | Positive | -10.8% | Q3 results plus FDA 510(k) clearance and portfolio, liquidity improvements. |
| Nov 03 | Product launch | Positive | +4.7% | Launch of OsseoSculpt biologic aligned with SINAPTIC wedge system rollout. |
| Oct 20 | FDA clearance | Positive | -15.4% | FDA 510(k) clearance for SINAPTIC Foot & Ankle Osteotomy Wedge System. |
Recent positive operational and regulatory milestones often coincided with negative price reactions, while some product launches and investor events saw modest gains, indicating a tendency toward selling on good news.
Over the last few months, SINTX reported several milestones, including FDA 510(k) clearance for its SINAPTIC Foot & Ankle system on October 20, 2025 and the launch of OsseoSculpt in Q4. Despite these positives, shares fell 15.4% after the October clearance and 10.79% following the Q3 update on November 13, 2025, while the OsseoSculpt launch saw a 4.7% gain. The AI-tagged SiN/PEEK supply agreement on December 1, 2025 produced a 21.2% drop, reinforcing this sell-on-good-news pattern.
Regulatory & Risk Context
An effective S-3 resale registration filed on October 23, 2025 covers up to 1,741,539 shares from selling stockholders. The company itself is not selling shares and would receive up to $8.3 million only if the registered warrants, with exercise prices around $4.79 and just above $4.31, are exercised for cash. This structure focuses on potential warrant exercise proceeds rather than primary issuance.
Market Pulse Summary
The stock dropped -21.2% in the session following this news. A negative reaction despite operationally positive news fits a pattern where SINTX often traded lower after favorable updates, such as the 21.2% drop following this SiN/PEEK announcement and declines after prior FDA milestones. The market may have focused on existing overhang from the S-3 resale registration for 1,741,539 shares and the possibility of up to $8.3 million in warrant exercise proceeds, even though the company was not selling shares directly.
Key Terms
additive manufacturing technical
radiolucency medical
osteogenic medical
antipathogenic medical
peek technical
AI-generated analysis. Not financial advice.
Milestone enables immediate production of SiN/PEEK custom devices
SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company, today announced that it has signed a supply agreement with Evonik Corporation (“EVONIK”), a global leader in high‑performance polymers, to manufacture the Company’s proprietary silicon nitride–PEEK compound (SiN/PEEK) (U.S. Patent No. 10,806,831) engineered for AI‑assisted additive manufacturing of patient‑specific implants that will be produced using equipment already in place at SINTX’s U.S.-based production facility.
Under the agreement, EVONIK will produce SiN/PEEK compound leveraging its commercial-scale capability to SINTX’s specifications, enabling the Company to immediately begin manufacturing AI‑designed, 3D‑printed, patient‑specific implants. SINTX has already received physician requests to provide humanitarian‑use vertebral body replacement (VBR) implants for orthopedic and neurosurgical oncology patients following tumor resections in the spine. In addition, the Company intends to use the SiN/PEEK compound to support regulatory clearances of patient matched and traditional subtractive manufactured implantable devices.
Eric K. Olson, Chairman, President & CEO of SINTX, said, “This agreement with EVONIK is another pivotal moment for SINTX and for the field of patient‑specific implants. By combining EVONIK’s industrial‑scale PEEK polymer manufacturing expertise with SINTX’s silicon nitride biomaterial manufacturing capabilities, we can deliver next‑generation implants that address critical needs in trauma, spine, oncology, and beyond. We believe SiN/PEEK offers compelling advantages over standard PEEK, including antipathogenic surface characteristics, osteogenic potential, and improved visualization—features that matter in complex, high‑risk procedures.”
Marc Knebel, head of EVONIK’s Medical Devices & Systems market segment, said, “We are excited to support SINTX in bringing a high‑performance SiN/PEEK composite filament to market for additive and subtractive manufacturing of regulated medical devices. This is another example of enabling innovation that EVONIK has delivered to improve medical outcomes. Our collaboration is designed to provide consistent quality, supply reliability, and scalability—foundational elements for our continued broader collaboration and data generation to support future medical device market work.”
Why SiN/PEEK for Patient-Specific Implants
SINTX’s silicon nitride has been studied for its antipathogenic behavior and osteogenic properties, while PEEK composites are valued for radiolucency and mechanical tunability. The SiN/PEEK combination aims to deliver:
- Antipathogenic surface behavior to help reduce microbial adherence on implant surfaces.
- Osteogenic support to promote bone on-growth and integration.
- Improved visualization vs. standard PEEK for intra-operative and post-operative imaging.
- Design freedom via AI-assisted, additive manufacturing for patient-specific geometries.
- Scalable, consistent filament to support high-mix, low-volume production typical of patient-specific workflows.
With today’s supply agreement, the parties envision making SiN/PEEK compound available to other qualified manufacturers for complex implant indications where silicon nitride’s attributes may add clinical and economic value.
SINTX’s near‑term humanitarian efforts are focused on trauma and oncology indications for post‑tumor resection cases, where surgeons face challenging anatomy and infection risk, and where patient‑specific designs may facilitate better fit, fixation and overall clinical outcomes, stated Dr. Ryan Bock, SINTX Chief Technology Officer. “We’re responding to real‑world surgeon requests in oncology‑related care. Our immediate focus is on humanitarian‑use cases while we build the quality systems, regulatory files, and production capacity to expand into additional indications through appropriate FDA pathways.”
For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
About EVONIK
EVONIK Business High Performance Polymers, including its affiliate Evonik Operations GmbH, is one of the world leaders in specialty chemicals companies and active in over 100 countries. EVONIK has more than 30 major production sites in the U.S. and Canada, as well as numerous offices, labs, warehouses and distribution centers, employing about 5,000 people in North America. In 2024, the North America region generated
About SINTX
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. With thousands of medical devices implanted since 2008 and nearly two decades of peer-reviewed research, SINTX has established itself as a leader in high-performance biomaterials that enhance clinical outcomes and patient safety. Supported by a strong patent portfolio, U.S.-based manufacturing, and strategic industry partnerships, the company continues to expand its technology platform through innovation and market diversification, including the recently FDA-cleared SINAPTIC® Foot & Ankle Implant System for reconstructive surgery.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the Company’s ability to manufacture SiN/PEEK composite materials and patient-specific implants; the timing, scope, and expected benefits of the Company’s supply agreement with Evonik; anticipated product performance attributes of the SiN/PEEK compound and related additive-manufacturing workflows; the Company’s plans to pursue regulatory clearances for patient-specific and traditionally manufactured implantable devices; expectations regarding humanitarian-use vertebral body replacement implants; the potential availability of SiN/PEEK materials to additional manufacturers; the projected clinical, operational, or economic advantages of SiN/PEEK compared with standard PEEK; and the Company’s expectations concerning quality-system development, production scale-up, broader market opportunities, and future indications. Forward-looking statements are based on current assumptions and are often identified by words such as “may,” “will,” “could,” “should,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “project,” “target,” “aim,” and similar expressions. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected, including risks related to manufacturing readiness, quality-system development, supply-chain reliability, EVONIK’s third-party performance, regulatory requirements and the timing or outcome of FDA submissions, clinical adoption of patient-specific implants, surgeon training and utilization, competitive technologies, intellectual-property protection, market acceptance, pricing and reimbursement dynamics, and macroeconomic or industry-specific conditions. Statements regarding potential antipathogenic or osteogenic attributes of silicon nitride refer to general material-level research and do not imply regulatory clearance or clinical benefit for any specific device or indication. Additional risks and uncertainties are described in SINTX’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, available at www.sec.gov. Forward-looking statements speak only as of the date of this release, and SINTX undertakes no obligation to update them, except as required by law.
SINTX Contacts:
Jack Perkins or Maria Hocut
KCSA Strategic Communications
Sintx@kcsa.com
SINTX Technologies, Inc.
801.839.3502
IR@sintx.com
FAQ
What did SINTX (NASDAQ:SINT) announce on December 1, 2025?
How does the Evonik supply agreement affect SINTX’s production timeline for patient‑specific implants?
What clinical benefits does SINTX claim for SiN/PEEK versus standard PEEK?
Which indications is SINTX initially targeting with SiN/PEEK implants?
Will SiN/PEEK be available beyond SINTX for other manufacturers?
